Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $80 from $77 and keeps an In Line rating on the shares after Edwards delivered what the firm says was “a solid quarter with revenues surpassing expectations.” The company’s FY25 guidance raise signals confidence in continued growth, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $79 from $78 at Baird
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Edwards Lifesciences price target raised to $94 from $85 at Deutsche Bank
- Edwards Lifesciences price target raised to $85 from $80 at JPMorgan